22 October 2026. Linklaters is advising QIAGEN N.V. on its agreement with EQT Private Equity regarding a public takeover offer, to be made entirely in cash, for all outstanding QIAGEN shares at an offer price of EUR 46.50 per share. The bidder is a holding company indirectly controlled by the EQT XI fund, with further indirect stakes held by the co-investors Luxinva S.A., a wholly owned subsidiary of the Abu Dhabi Investment Authority, and CPP Investment Board Europe Inc., a wholly owned subsidiary of the Canada Pension Plan Investment Board.

The transaction values QIAGEN at an enterprise value of approx. EUR 10.8 billion (approx. USD 12.1 billion at current exchange rates), including net debt of approx. USD 1.1 billion.

QIAGEN N.V., a holding company based in the Netherlands, is a leading global provider of "Sample to Insight" solutions that enable customers to extract and analyse molecular information from biological samples. QIAGEN serves more than 500,000 customers worldwide in life sciences and clinical healthcare. The company employs around 5,400 people at more than 35 locations.

An international cross-practice Linklaters team led by Corporate/M&A partner Staffan Illert and Prof. Daniela Seeliger (Antitrust & Foreign Investment) advised QIAGEN on this complex transaction. The team also included partners Dr. David dos Santos Goncalves (Antitrust & Foreign Investment) and Dr. Alexander Schlee (Capital Markets), counsel Ben Bauer (Antitrust & Foreign Investment, New York), Ulli Janssen (Corporate/M&A), Tobias Rump (Antitrust & Foreign Investment), Will Creswell (Capital Markets) and Dr. Urs Lewens (Banking), managing associates Dr. Kevin Eisenschmidt (Corporate/M&A) and Catrin Retzmann (Capital Markets), and associates Kathy Choi (London) and Dr. Theresa Noßke (both Antitrust & Foreign Investment).

This text was automatically translated from the German original.